Time is Limited - Act Now
Time is Limited
Act Now
Studies link TEPEZZA® (also known as Teprotumumab) with serious hearing complications
Victims of one of the following hearing problems after taking TEPEZZA® for thyroid eye disease should check eligibility for compensation now:
- Hearing loss—also called hyperacusis
- Tinnitus—or ringing in the ears
- Autophony—or enhanced perception of own bodily sounds, like voice & breathing
- Sensations of ears being "plugged" or "full"
We urge victims that suffer hearing problems after taking TEPEZZA® for thyroid eye disease to get a free, private case evaluation.
Victims that experienced hearing loss (or other hearing problems) after receiving IV infusions of TEPEZZA®—the first-ever FDA-approved drug for thyroid eye disease (TED)---should pay attention to this crucial information.
TEPEZZA® has shown to be an effective drug for treating Thyroid Eye Disease (TED), typically caused by Grave's disease.
However, the manufacturer may have failed to properly warn patients and their doctors about the severity of hearing-related risks.
Some studies reported that as much as 65% of patients who received TEPEZZA® infusions suffered hearing-related side effects—many of which appear to be irreversible.
The manufacturer of TEPEZZA®, Horizon Therapeutics, reported in their pre-market and post-market clinical trials that only 10% of those who received TEPEZZA® reported hearing complications—which happens to be far less than what many other recent studies show.
Also, the manufacturer reported that the hearing-related side effects reported in their own clinical trials were mostly "temporary", whereas other studies have reported that hearing-related side effects were persisting even after discontinuation of TEPEZZA®—and may be permanent.
For many patients suffering from thyroid eye disease (TED), the reported 10% rate of temporary hearing problems during treatments was well worth the risk.
But numerous published studies have come to light, showing that hearing-related risks could be as high as 65% in patients.
Those that suffered permanent hearing loss or tinnitus due to TEPEZZA® infusions may incur astronomical healthcare costs for the remainder of their life.
An Update to the TEPEZZA® and Thyroid Eye Disease (TED) Relationship
The US FDA has given the green light for Horizon Therapeutics’ TEPEZZA® (teprotumumab-trbw) label to include new information about treating thyroid eye disease (TED) patients, no matter how long they have had the disease or how active it is.
TEPEZZA®, an insulin-like growth factor-1 receptor inhibitor, is the first and only medicine FDA-approved for TED. This rare autoimmune disease can worsen over time, affecting vision and causing debilitation.
Horizon Therapeutics' CEO, Tim Walbert, shared, “We collaborated closely with the FDA for this important label update, showing how TEPEZZA® can help people with thyroid eye disease, regardless of how active or long-lasting their condition is."
Previously, TEPEZZA® was already approved for treating thyroid eye disease, but this new label update emphasizes its use for all patients dealing with the full range of the disease's effects.
Health insurance companies are already trying to find ways to limit their liability and coverages for these new, advanced hearing tests and hearing aids due to their ever-increasing costs.
There is a very small window of time for victims to seek financial compensation after an injury, and the time window for pursuing a case is different in each state.
Those who qualify may request a free, private case evaluation by a personal injury attorney!
Find Out if You Qualify
*Consent: By clicking the "SUBMIT" button, I consent to receive recurring auto dialed and/or text messages from Shield Justice Online or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the Shield Justice Online Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 27 msgs per month.
We urge victims that suffer hearing problems after taking TEPEZZA® for thyroid eye disease to get a free, private case evaluation.
Victims that experienced hearing loss (or other hearing problems) after receiving IV infusions of TEPEZZA®—the first-ever FDA-approved drug for thyroid eye disease (TED)---should pay attention to this crucial information.
TEPEZZA® has shown to be an effective drug for treating Thyroid Eye Disease (TED), typically caused by Grave's disease.
However, the manufacturer may have failed to properly warn patients and their doctors about the severity of hearing-related risks.
Some studies reported that as much as 65% of patients who received TEPEZZA® infusions suffered hearing-related side effects—many of which appear to be irreversible.
The manufacturer of TEPEZZA®, Horizon Therapeutics, reported in their pre-market and post-market clinical trials that only 10% of those who received TEPEZZA® reported hearing complications—which happens to be far less than what many other recent studies show.
Also, the manufacturer reported that the hearing-related side effects reported in their own clinical trials were mostly "temporary", whereas other studies have reported that hearing-related side effects were persisting even after discontinuation of TEPEZZA®—and may be permanent.
For many patients suffering from thyroid eye disease (TED), the reported 10% rate of temporary hearing problems during treatments was well worth the risk.
But numerous published studies have come to light, showing that hearing-related risks could be as high as 65% in patients.
Those that suffered permanent hearing loss or tinnitus due to TEPEZZA® infusions may incur astronomical healthcare costs for the remainder of their life.
An Update to the TEPEZZA® and Thyroid Eye Disease (TED) Relationship
The US FDA has given the green light for Horizon Therapeutics’ TEPEZZA® (teprotumumab-trbw) label to include new information about treating thyroid eye disease (TED) patients, no matter how long they have had the disease or how active it is.
TEPEZZA®, an insulin-like growth factor-1 receptor inhibitor, is the first and only medicine FDA-approved for TED. This rare autoimmune disease can worsen over time, affecting vision and causing debilitation.
Horizon Therapeutics' CEO, Tim Walbert, shared, “We collaborated closely with the FDA for this important label update, showing how TEPEZZA® can help people with thyroid eye disease, regardless of how active or long-lasting their condition is."
Previously, TEPEZZA® was already approved for treating thyroid eye disease, but this new label update emphasizes its use for all patients dealing with the full range of the disease's effects.
Health insurance companies are already trying to find ways to limit their liability and coverages for these new, advanced hearing tests and hearing aids due to their ever-increasing costs.
There is a very small window of time for victims to seek financial compensation after an injury, and the time window for pursuing a case is different in each state.
Those who qualify may request a free, private case evaluation by a personal injury attorney!
100% Free & Secure Case Evaluations
Don’t suffer hearing loss without support any longer—we fight for justice!
Victims that suffer serious hearing diagnoses after taking TEPEZZA® for thyroid eye disease should have the opportunity to address the manufacturers and get compensation for their losses.
Please seek the advice of a medical professional before making health care decisions. This advertisement is not associated with any government agency.
www.shieldjusticeonline.com is the property of Shield Legal LLC. 7180 S Pollock Drive, 2nd Floor, Las Vegas, NV 89119
This website is not part of the Facebook website or Facebook, Inc. Additionally, this site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, INC.
ATTORNEY ADVERTISING. This Website is not intended to provide medical advice. Consult your doctor or physician before starting or stopping any medication.
Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. are not an indication of future results. Every submissions is evaluated on its own facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Shield Justice Online does not itself provide legal services. Submissions will be referred to third party attorneys and law firms. Do not rely on this advertisement in making any medical decision. Please call your physician before making any medical decision, including altering your use of any drug. Court costs and expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement or dramatization, and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyers' credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under the age of 13("Children").
Privacy Policy | Terms and Conditions | CCPA Privacy Notice | Do Not Sell My Info
©2024 Shield Justice Online. All Rights Reserved